Diazoxide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 21: | Line 21: | ||
''' [[Diazoxide indications and usage|Indications and Usage]]''' | ''' [[Diazoxide indications and usage|Indications and Usage]]''' | ||
'''| [[Diazoxide dosage and administration|Dosage and Administration]]''' | '''| [[Diazoxide dosage and administration|Dosage and Administration]]''' | ||
'''| [[Diazoxide contraindications|Contraindications]]''' | '''| [[Diazoxide contraindications|Contraindications]]''' | ||
'''| [[Diazoxide warnings and precautions|Warnings and Precautions]]''' | '''| [[Diazoxide warnings and precautions|Warnings and Precautions]]''' | ||
| Line 31: | Line 30: | ||
'''| [[Diazoxide clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Diazoxide clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Diazoxide nonclinical toxicology|Nonclinical Toxicology]]''' | '''| [[Diazoxide nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[Diazoxide how supplied storage and handling|How Supplied/Storage and Handling]]''' | '''| [[Diazoxide how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[Diazoxide labels and packages|Labels and Packages]]''' | '''| [[Diazoxide labels and packages|Labels and Packages]]''' | ||
Revision as of 22:39, 26 February 2014
| Diazoxide |
|---|
| PROGLYCEM® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Diazoxide |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Diazoxide, click here.
Synonyms / Brand Names: PROGLYCEM®
Overview
Diazoxide (INN; brand name Proglycem[1]) is a potassium channel activator, which causes local relaxation in smooth muscle by increasing membrane permeability to potassium ions. This switches off voltage-gated calcium ion channels which inhibits the generation of an action potential.
Category
Sulfonamides;Vasodilators;Potassium channel openers;Benzothiadiazines;Organochlorides,Cardiovascular Drugs
FDA Package Insert
PROGLYCEM (diazoxide) suspension
Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | How Supplied/Storage and Handling | Labels and Packages
Mechanism of Action
References
Template:Nonsympatholytic vasodilatory antihypertensives Template:Other therapeutic products Template:Channel openers